The global nasal drug delivery technology market is projected to reach USD 64.20 Billion by 2021 from USD 44.00 Billion in 2016, at a CAGR of 6.5% during the forecast period. Increasing patient preference for nasal drug delivery as a result of easy administration & better efficacy and growing adoption of self-administration practices are some of the major factors driving the growth of the market.
Furthermore, growth among over-the-counter nasal drugs and increasing focus on alternative routes of drug delivery such as nasal drug delivery offer significant growth opportunities for player operating in the market. On the other hand, complications associated with the overuse of nasal sprays may restraint the growth of the market.
The market is segmented based on dosage form, therapeutic application, end user, system, container, and region. On the basis of system, the market is segmented into multi-dose systems, bi-dose systems, and unit-dose systems. In 2016, the multi-dose drug delivery systems segment is expected to account for the largest share of the market. This can primarily be attributed to the growing preference for multi-dose drug delivery as these systems provide quick and effective delivery of drugs into the bloodstream.
On the basis of container, the market is segmented into pressurized and non-pressurized containers. In 2016, the non-pressurized containers segment is expected to account for the largest share of the market. This can be primarily attributed to advantages such as better versatility and reliability, instant availability, self-containment, better portability, and low-cost medical aerosol delivery. In addition, the increasing usage of these devices for the treatment of reversible airflow obstruction resulting from asthma and chronic obstructive pulmonary disease (COPD) is expected to further drive the growth of this market in the coming years.
On the basis of dosage form, the market is segmented into the sprays, drops & liquids, nasal powders, and nasal gels. In 2016, the nasal sprays segment is expected to account for the largest share of the market. The large share of this market segment can be attributed to factors such as increased patient compliance due to reduced irritation caused by dust and pollen, affordable prices of nasal sprays, and delivery of large doses of drugs.
On the basis of therapeutic application, the market is segmented into allergic and non-allergic rhinitis, nasal congestion, vaccination, and other therapeutic applications (osteoporosis, pain management, and sexual dysfunction). The allergic and non-allergic rhinitis segment is expected to register the highest CAGR during the forecast period. The high growth in this segment can primarily be attributed to the increasing prevalence of allergic and non-allergic rhinitis and growing preference for nasal drugs for its treatment.
On the basis of end user, the market is segmented into hospitals and home care settings. In 2016, the home care settings segment is expected to account for the largest share of the market, primarily due to the increasing preference for self-administration among patients.
Aegis Therapeutics LLC
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Regulatory Scenario
7 Global Nasal Drug Delivery Technology Market, By Dosage Form
8 Global Nasal Drug Delivery Technology Market, By Containers
9 Global Nasal Drug Delivery Technology Market, By Systems
10 Global Nasal Drug Delivery Technology Market, By Therapeutic Application
11 Global Nasal Drug Delivery Technology Market, By End User